Moreover, LILRB4, a leukocytic immunoglobulin-like receptor belonging to the LILRB family,386–389 has shown promising results in preclinical studies.389 The LILRB family is expressed on AML cells and has been reported to be uniquely expressed on normal monocytic cells at the promonocyte stage of development.390 An interesting first-in-human study presented at the last ASH congress (San Diego, December 2024) demonstrated that LILRB4 STAR-T therapy is a promising approach in LILRB4 -positive R/R AML patients.391 Further data from the Phase II trial is eagerly awaited. Here, LILRB4 is linked to acute myeloid leukemia.